Literature DB >> 1347659

Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.

J Dingemanse1, A Korn, J P Pfefen, T W Güntert.   

Abstract

The effects of high single doses of moclobemide (300, 450 and 600 mg given at the end of a standardized meal) on plasma levels of several catecholamines and their deaminated metabolites, and on plasma levels of pituitary hormones were determined in eight healthy young male volunteers in a randomized, double-blind, placebo-controlled study. Assessment of the i.v. tyramine potentiation and determination of the plasma levels of moclobemide were also performed. The tyramine sensitivity factor at 2 h after dosing was about 2.1, with no significant differences between the doses used. The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA. No clear differences were detected between the moclobemide doses. Prolactin plasma concentrations were only slightly increased after the two higher doses. The plasma concentrations of moclobemide were very much in agreement with those found in previous studies under similar experimental conditions. Thus, single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347659     DOI: 10.1007/bf02246235

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

1.  Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.

Authors:  A Korn; M Da Prada; W Raffesberg; S Gasic; H G Eichler
Journal:  J Cardiovasc Pharmacol       Date:  1988-01       Impact factor: 3.105

2.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

  3 in total
  7 in total

1.  Effect of oral linezolid on the pressor response to intravenous tyramine.

Authors:  Mireille V Cantarini; Catherine J Painter; Elaine M Gilmore; Catherine Bolger; Claire L Watkins; Andrew M Hughes
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.

Authors:  A D Van Haarst; J M Van Gerven; A F Cohen; M De Smet; A Sterrett; K L Birk; A L Fisher; M E De Puy; M R Goldberg; D G Musson
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 4.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

5.  Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

Authors:  N H Holford; T W Guentert; J Dingemanse; L Banken
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

Review 6.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

7.  Chronic Serotonergic Overstimulation Mimicking Panic Attacks in a Patient with Parkinson's Disease Receiving Additional Antidepressant Treatment with Moclobemide.

Authors:  Marc Praetner; Timo Schiele; Lukas Werle; Janina Kuffer; Sandra Nischwitz; Martin E Keck; Stefan Kloiber
Journal:  Case Rep Psychiatry       Date:  2021-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.